Drug Development in the New Era: A Global Perspective
4th International conference on phase 1 and early phase clinical trials
March 1-2, 2018 | Hyatt Regency Hong Kong, Tsim Sha Tsui, 18 Hanoi Road, Kowloon, Hong Kong
Dr. Mario Tanguay, BPharm, PhD
Vice President of Strategic Development,
Syneos Health, Montreal, Canada
Dr. Mario Tanguay has over 20 years of experience in clinical drug development and is an expert in the area of clinical pharmacology. Dr. Tanguay is currently the Vice President of Strategic Development at Syneos Health and is Responsible for vocational training in clinical research at the Faculty of Pharmacy at University of Montreal. Dr. Tanguay was previously Vice President of Clinical Pharmacology and Scientific & Regulatory Affairs at inVentiv Health, and held various clinical research managerial and scientific positions at MDS Pharma Services, Pharmacia, and Wyeth-Ayerst Research. He has also worked as a community pharmacist for many years.
Throughout his career, Dr. Tanguay has served as clinical pharmacologist in over a thousand pharmacokinetic or Phase I trials. He has also assisted many pharmaceutical and biotech companies in preparing their pre-IND submission and early clinical or clinical pharmacology development plan, and has interacted with different regulatory authorities, including the US FDA, Health Canada, ANVISA (Brazil), and EU agencies. Dr. Tanguay holds a Bachelor’s Degree in Pharmacy and earned master and doctorate degrees in Pharmacology from the University of Montreal. Dr. Tanguay has authored or co-authored over 80 articles and abstracts and has made numerous presentations on the national and international levels.
Day Two: Trends in the Design and Conduct of First-in-Human Trials